Henan Kanda Pharmaceutical Co., Ltd. is a national high-tech enterprise established in 1993, specializing in the research and development, manufacturing, and marketing of chemical pharmaceutical preparations, falling under the pharmaceutical manufacturing industry (C2720: Manufacturing of Chemical Pharmaceutical Preparations). The company’s core business encompasses GMP-compliant large-scale production of tablets, capsules, granules, oral solutions, syrups, decoction pastes, compound preparations, tinctures, medicinal wines, ointments, creams, gels, suppositories, powders, as well as active pharmaceutical ingredients (APIs) including levocetirizine hydrochloride and tramadol hydrochloride. Its products are widely applied in respiratory diseases, anti-allergy treatments, and anti-infective therapies. Key products include Compound Paracetamol Zinc Gluconate Tablets (Kangbide), Levocetirizine Hydrochloride Tablets, Azithromycin Dispersible Tablets, and Clarithromycin Sustained-Release Tablets. Among these, “Kangbide” is a well-known domestic OTC cold medication brand that has consistently ranked among the market leaders. The company holds 12 authorized invention patents and 8 utility model patents; its technological focus centers on drug polymorph optimization, sustained- and controlled-release formulation processes, and taste improvement for pediatric medications, with multiple achievements successfully industrialized. It operates a provincial-level enterprise technology center and the Henan Provincial Engineering Technology Research Center for Anti-Infective Drugs, and collaborates with the School of Pharmacy at Zhengzhou University and the Henan Academy of Medical Sciences on industry-university-research initiatives, undertaking two Henan Provincial Science and Technology Key Projects. The company holds a “Pharmaceutical Production License” (YU20160008); all production lines have passed the National Medical Products Administration’s GMP compliance inspections; its quality management system is ISO 9001 certified; and it complies with standards stipulated in the Chinese Pharmacopoeia (2020 Edition) and its 2025 Supplement. Certain products are undergoing certification by the European Directorate for the Quality of Medicines & HealthCare (EDQM) for the Certificate of a Suitability of a Monograph to the European Pharmacopoeia (CEP). Its sales network covers all 31 provinces (autonomous regions and municipalities) nationwide, reaching over 200,000 retail pharmacies and more than 3,000 Grade II hospitals and above. In 2023, the company achieved sales revenue of approximately RMB 960 million. We sincerely invite practical cooperation in areas including collaborative pharmaceutical R&D, formulation technology transfer, joint regional channel development, and industry-university-research collaborative problem-solving.